Revolution Medicines’ success in pancreatic cancer has ignited interest in a new type of medicine that’s sending dealmaking into overdrive.

Learn how structured molecular tumor boards, standardized genomic testing, and data pipelines improve targeted treatment ...

Oncologists have discovered that lung cancer cells can change their identity to resist treatment. Research published in Molecular Oncology reveals how lung cancer cells can become more aggressive and ...

A small clinical trial led by Dana-Farber Cancer Institute researchers has put a Salk Institute idea to the test in patients: ...

Positive Phase 1 data confirm MP0317’s tumor-localized CD40 activation with a favorable safety profile in patients with advanced cancer ...

Cancer scientists have discovered that lung cancer cells can change their identity to resist treatment. Research published today [27 May] in Molecular Oncology reveals how lung cancer cells can become ...

NeoCircle validates Pathlight MRD ctDNA detection in early breast cancer, predicting progression months to years ahead of ...

When it comes to cancer, tumor suppressor genes are usually thought of as the "good guys." These genes make proteins that ...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of ...